U.S. Patent Office Significantly Extends the Term of Three RegeneRx Patents
PR Newswire

ROCKVILLE, Md., Nov. 3, 2014 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX)("the Company" or "RegeneRx") today announced that the U.S. Patent and Trademark Office (USPTO) has notified the Company that it is extending the terms of three U.S. patents issued to RegeneRx based on new rules recently implemented within the America Invents Act Technical Corrections Act that aim to restore time of exclusivity often lost during lengthy patent prosecutions in the United States.

In the case of U.S. Patent No. 8,716,215, Method of Treating or Preventing Tissue Deterioration, Injury or Damage Due to a Neuro-, Muscular- or Neuro-Muscular-Degenerative Disease, or Restore Tissue Adversely Affected by Said Disease, the patent expiration has been extend by 1,692 days (4.6 years) to August 31, 2030.

In the case of U.S. Patent No. 8,399,609, Treating or Preventing Extracellular Matrix Build-up (in the heart), the patent expiration has been extended by 1,402 days (3.8 years) to January 7, 2029.

In the case of U.S. Patent No. 8,383,576, LKKTET and/or LKKTNT Peptide Compositions which are Lyophilized or in a Form Capable of Being Lyophilized, the patent expiration has been extended by 1,354 days (3.7 years) to March 4, 2030.

"We are pleased that we have been able to restore a significant amount of time for three of our U.S. patents pursuant to recently implemented regulations at the USPTO.  Patent term exclusivity now is being more fairly extended for companies that diligently pursue the patent application process, which sometimes may take many years to conclude, especially relating to the discovery of novel and complex technologies," stated J.J. Finkelstein, RegeneRx's president and chief executive officer.

About RegeneRx Biopharmaceuticals, Inc. (www.regenerx.com)

RegeneRx is focused on the development of a novel therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair and regeneration. RegeneRx currently has three drug candidates in clinical development for ophthalmic, cardiac, CNS and dermal indications, strategic licensing agreements in China, the EU, and in other Pan Asia countries, including Korea, Japan and Australia, and has an extensive worldwide patent portfolio covering its products.

Forward-Looking Statements

Any statements in this press release that are not historical facts are forward-looking statements made under the provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements concerning clinical development and future commercialization of our product candidates or the ability to maintain, defend or enforce any of our issued patents. There can also be no assurance that any issued patent will ultimately be of commercial benefit.  Any forward-looking statements involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Please view these and other risks described in the Company's filings with the Securities and Exchange Commission ("SEC"), including those identified in the "Risk Factors" section of the annual report on Form 10-K for the year ended December 31, 2013, and subsequent quarterly reports filed on Form 10-Q, as well as other filings it makes with the SEC. Any forward-looking statements in this press release represent the Company's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. The Company specifically disclaims any obligation to update this information, as a result of future events or otherwise, except as required by applicable law.

SOURCE RegeneRx Biopharmaceuticals, Inc.